Newsroom

News & Press Releases


CeloNova BioSciences Inc. Named one of the Top 10 Cardiovascular Device Companies of 2019 by MedTech Outlook

San Antonio - April 5 2019

MedTech Outlook recognizes CeloNova BioSciences, Inc. as a pioneer at the forefront of cardiovascular innovation by naming the company as one of the top 10 cardiovascular companies of 2019.

CeloNova’s foundation of innovation has led to the successful manufacturing and marketing of a family of products, including the COBRA PzF NanoCoated Coronary Stent (NCS), based upon its proprietary Polyzene-F (PzF) nanocoating technology, a revolutionary surface coating designed to optimize implant interaction within the body.


Browse Our Archives

COBRA PzF NanoCoated Coronary Stent @ TCT 2019

September 25-29, San Francisco, CA

TCT Number 941

Dr. Luc Maillard will be presenting a poster titled "MAPT (Mono Antiplatelet Therapy) as Regular Regimen After Cobra PzF™ NanoCoated Coronary Stent (NCS) Implantation" at TCT.

When: September 27, 2019
Where: Moscone South, Lower Level, Hall B-C
Time: 9:15-10:45 AM

Register Today